Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LNTH NASDAQ:MIRM NASDAQ:RYTM NASDAQ:TYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLNTHLantheus$103.41+0.6%$98.94$47.25▼$111.86$6.73B-0.06967,292 shs1.15 million shsMIRMMirum Pharmaceuticals$128.31+5.2%$103.20$49.22▼$129.00$7.82B0.48932,304 shs902,364 shsRYTMRhythm Pharmaceuticals$114.46+2.5%$93.75$64.65▼$122.20$7.84B1.88815,052 shs998,560 shsTYRATyra Biosciences$31.94+3.5%$31.58$9.60▼$40.65$1.90B0.76967,149 shs743,887 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLNTHLantheus-6.43%-6.17%+1.82%+31.69%+29.81%MIRMMirum Pharmaceuticals-2.93%-0.89%+30.41%+27.45%+144.16%RYTMRhythm Pharmaceuticals-2.18%+1.49%+29.26%+28.87%+69.79%TYRATyra Biosciences+0.78%-3.89%+15.84%-18.21%+208.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLNTHLantheus$103.41+0.6%$98.94$47.25▼$111.86$6.73B-0.06967,292 shs1.15 million shsMIRMMirum Pharmaceuticals$128.31+5.2%$103.20$49.22▼$129.00$7.82B0.48932,304 shs902,364 shsRYTMRhythm Pharmaceuticals$114.46+2.5%$93.75$64.65▼$122.20$7.84B1.88815,052 shs998,560 shsTYRATyra Biosciences$31.94+3.5%$31.58$9.60▼$40.65$1.90B0.76967,149 shs743,887 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLNTHLantheus-6.43%-6.17%+1.82%+31.69%+29.81%MIRMMirum Pharmaceuticals-2.93%-0.89%+30.41%+27.45%+144.16%RYTMRhythm Pharmaceuticals-2.18%+1.49%+29.26%+28.87%+69.79%TYRATyra Biosciences+0.78%-3.89%+15.84%-18.21%+208.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLNTHLantheus 2.73Moderate Buy$101.86-1.50% DownsideMIRMMirum Pharmaceuticals 2.93Moderate Buy$143.4011.76% UpsideRYTMRhythm Pharmaceuticals 2.76Moderate Buy$136.4019.17% UpsideTYRATyra Biosciences 2.87Moderate Buy$47.0047.15% UpsideCurrent Analyst Ratings BreakdownLatest TYRA, RYTM, MIRM, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2026RYTMRhythm Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$137.00 ➝ $141.007/7/2026MIRMMirum Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$142.00 ➝ $148.007/2/2026MIRMMirum Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$115.00 ➝ $125.006/29/2026LNTHLantheus Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$115.006/23/2026MIRMMirum Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)6/17/2026RYTMRhythm Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/17/2026TYRATyra Biosciences JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$56.006/16/2026RYTMRhythm Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$143.00 ➝ $151.006/15/2026RYTMRhythm Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$133.006/15/2026MIRMMirum Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/15/2026RYTMRhythm Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$144.00 ➝ $155.00(Data available from 7/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLNTHLantheus$1.54B4.37$6.01 per share17.21$16.43 per share6.29MIRMMirum Pharmaceuticals$521.31M15.01$0.05 per share2,463.56$6.12 per share20.97RYTMRhythm Pharmaceuticals$189.76M41.34N/AN/A$2.08 per share55.03TYRATyra BiosciencesN/AN/AN/AN/A$4.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLNTHLantheus$233.56M$4.1524.9219.22N/A18.05%29.32%15.00%8/5/2026 (Estimated)MIRMMirum Pharmaceuticals-$23.36M-$13.61N/A557.87N/A-140.24%-11.28%-3.84%7/30/2026 (Estimated)RYTMRhythm Pharmaceuticals-$196.54M-$3.13N/AN/AN/A-93.33%-203.25%-44.99%8/4/2026 (Estimated)TYRATyra Biosciences-$119.95M-$2.18N/AN/AN/AN/A-42.66%-39.79%8/13/2026 (Estimated)Latest TYRA, RYTM, MIRM, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q2 2026RYTMRhythm Pharmaceuticals-$0.82N/AN/AN/A$67.53 millionN/A7/30/2026Q2 2026MIRMMirum Pharmaceuticals-$0.7410N/AN/AN/A$166.03 millionN/A5/13/2026Q1 2026TYRATyra Biosciences-$0.60-$0.64-$0.04-$0.64N/AN/A5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/6/2026Q1 2026MIRMMirum Pharmaceuticals-$0.75-$13.43-$12.68-$13.43$148.21 million$159.88 million5/5/2026Q1 2026RYTMRhythm Pharmaceuticals-$0.86-$0.83+$0.03-$0.83$55.78 million$60.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLNTHLantheusN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLNTHLantheus0.472.832.64MIRMMirum Pharmaceuticals1.282.091.99RYTMRhythm PharmaceuticalsN/A4.173.89TYRATyra BiosciencesN/A20.4920.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLNTHLantheus99.06%MIRMMirum PharmaceuticalsN/ARYTMRhythm PharmaceuticalsN/ATYRATyra Biosciences84.14%Insider OwnershipCompanyInsider OwnershipLNTHLantheus1.70%MIRMMirum Pharmaceuticals8.32%RYTMRhythm Pharmaceuticals5.90%TYRATyra Biosciences12.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLNTHLantheus1,19365.11 million64.00 millionOptionableMIRMMirum Pharmaceuticals14060.98 million55.91 millionOptionableRYTMRhythm Pharmaceuticals14068.53 million64.49 millionOptionableTYRATyra Biosciences2059.47 million52.04 millionOptionableTYRA, RYTM, MIRM, and LNTH HeadlinesRecent News About These CompaniesIs Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?June 30, 2026 | finance.yahoo.comIs Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?June 30, 2026 | finance.yahoo.comNon-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsightJune 23, 2026 | finance.yahoo.comAnalysts Are Bullish on Top Healthcare Stocks: ClearPoint Neuro (CLPT), Tyra Bioscience (TYRA)June 20, 2026 | theglobeandmail.com5AM Venture Management LLC Buys 90,000 Shares of Tyra Biosciences, Inc. $TYRAJune 18, 2026 | marketbeat.comIs Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism?June 12, 2026 | finance.yahoo.comWolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)June 1, 2026 | finance.yahoo.comWolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)June 1, 2026 | insidermonkey.comTYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAYMay 21, 2026 | prnewswire.comWolfe Research initiates coverage of Tyra Biosciences (TYRA) with peer perform recommendationMay 20, 2026 | msn.comTyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More SharesMay 17, 2026 | fool.comAssessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price MomentumMay 15, 2026 | finance.yahoo.comHot Picks: Cancer biotech stocks gain ground amid M&A activityMay 13, 2026 | bnnbloomberg.caBTyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comTyra Biosciences Reports First Quarter 2026 Financial Results and Recent HighlightsMay 13, 2026 | prnewswire.comTyra Biosciences to Participate in Upcoming Investor ConferencesMay 7, 2026 | prnewswire.comTyra Biosciences faces earnings test ahead of key trial dataApril 29, 2026 | investing.comTyra Bioscience, IncApril 25, 2026 | edition.cnn.comTyra Bioscience (TYRA) Receives a Buy from OppenheimerApril 25, 2026 | theglobeandmail.comGuggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug DabogratinibApril 24, 2026 | insidermonkey.comTyra Biosciences, Inc. ($TYRA) CEO 2025 Pay RevealedApril 17, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTYRA, RYTM, MIRM, and LNTH Company DescriptionsLantheus NASDAQ:LNTH$103.41 +0.59 (+0.57%) Closing price 04:00 PM EasternExtended Trading$103.30 -0.11 (-0.11%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Mirum Pharmaceuticals NASDAQ:MIRM$128.31 +6.40 (+5.25%) Closing price 04:00 PM EasternExtended Trading$128.31 0.00 (0.00%) As of 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Rhythm Pharmaceuticals NASDAQ:RYTM$114.46 +2.78 (+2.49%) Closing price 04:00 PM EasternExtended Trading$114.44 -0.02 (-0.01%) As of 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Tyra Biosciences NASDAQ:TYRA$31.94 +1.08 (+3.50%) Closing price 04:00 PM EasternExtended Trading$31.94 +0.00 (+0.02%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Apple and Broadcom Forge a Decade-Long Silicon Fortress SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity Palantir's CEO Just Called Out OpenAI and Anthropic Silicon Starvation: Amazon Feasts on Legacy GPUs GE Vernova’s Power Surge Turns the Grid Into an AI Trade 3 Quiet AI Revenue Accelerators With Sales Growth Outpacing Peers Abivax: Wall Street Catches Up to the Data Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
